Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
The present invention provides a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof. Specifically, the present invention provides a combined chimeric antigen receptor targeting CD19 and CD20, which comprises a scFv targeting CD19 and CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. The present invention provides a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and applications thereof. The experimental results show that the chimeric antigen receptor provided by the present invention shows extremely high killing ability against tumor cells. The chimeric antigen receptor of the present invention targets CD19 and/or CD20 positive cells and can be used to treat CD19 and/or CD20 positive B-cell lymphoma, leukemia and other diseases.
1. A method of treating a B-cell malignancy, the method comprising administering a T cell or a natural killer (NK) cell expressing a bispecific chimeric antigen receptor (CAR) to a subject in need thereof, the bispecific CAR comprising:
(i) an anti-CD20 antigen-binding region which comprises a light chain variable region (V L 1) and a heavy chain variable region (V H 1) having amino acid sequences set forth in SEQ ID NO: 4 and SEQ ID NO: 3, respectively, wherein V L 1 is located at the N-terminus of V H 1; and
(ii) an anti-CD19 antigen-binding region which comprises a light chain variable region (V L 2) and a heavy chain variable region (V H 2) having amino acid sequences set forth in SEQ ID NO: 5 and SEQ ID NO: 6, respectively, wherein V H 2 is located at the N-terminus of V L 2,
wherein the bispecific CAR comprises an amino acid sequence set forth in SEQ ID NO: 16.
2. The method of claim 1 , wherein the B-cell malignancy is non-Hodgkin's lymphoma.
3. The method of claim 1 , wherein the B-cell malignancy is chronic lymphocytic leukemia (CLL), B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B cell lymphoma (DLBCL), or combinations thereof.
4. The method of claim 1 , wherein the T cell or NK cell is allogeneic or autologous.
5. The method of claim 1 , wherein the B-cell malignancy is B-cell leukemia or B-cell lymphoma.